**Perioperative chemotherapy and advanced disease - increasing experience and new aspects**

**Location:** Room Vienna, North Hall (Level 1)

**Chairs:** P. Patel, Birmingham (GB)  
C.N. Sternberg, Rome (IT)  
J.A. Witjes, Nijmegen (NL)

**Aims and objectives of this session**

This session will highlight new data on systemic perioperative therapy and advanced bladder cancer, including chemotherapy, immunotherapy and prediction of outcome.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.

*170

**Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052**

**By:** Powles T.¹, Bellmunt J.², Castellano D.³, O’Donnell P.⁴, Grivas P.⁵, Vuky J.⁶, Plimack E.⁷, Hahn N.⁸, Balar A.⁹, Pang L.¹⁰, Savage M.¹⁰, Perini R.¹⁰, Keefe S.¹⁰, Bajarin D.¹¹, De Wit R.¹²

**Institutes:** ¹Barts Cancer Institute, Queen Mary University of London, Dept. of Experimental Cancer Medicine, London, United Kingdom, ²Dana-Farber Cancer Institute, Dept. of Genitourinary Oncology, Boston, United States of America, ³Hospital Universitario 12 De Octubre, Dept. of Medicine, Madrid, Spain, ⁴The University of Chicago Medical Centre, Dept. of Medicine, Chicago, United States of America, ⁵Cleveland Clinic, Dept. of Hematology and Oncology, Cleveland, United States of America, ⁶Oregon Health & Science University, Dept. of Oncology, Portland, United States of America, ⁷Fox Chase Cancer Center, Dept. of Hematology and Oncology, Philadelphia, United States of America, ⁸Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Dept. of Oncology and Urology, Baltimore, United States of America, ⁹Perlmutter Cancer Center, NYU Langone Medical Center, Dept. of Medicine, New York, United States of America, ¹⁰Merck & Co., Inc., Dept. of Clinical Oncology, Kenilworth, United States of America, ¹¹Memorial Sloan Kettering Cancer Center, Dept. of Medical Oncology, New York, United States of America, ¹²Erasmus MC Cancer Institute, Dept. of Urology and Oncology, Rotterdam, The Netherlands

171

**Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) vs. single agent and doublet chemotherapy (CT)**

**By:** Necchi A.¹, Raggi D.¹, Sonpavde G.², Giannatempo P.³, Mariani L.³, Galsky M.³, Bellmunt J.³, Miceli R.³

**Institutes:** ¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²UAB Comprehensive Cancer Center, Dept. of Medical Oncology & Hematology, Birmingham, United States of America, ³Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ⁵Mount Sinai School of Medicine, Tisch Cancer Institute, Dept. of Medical Oncology, New York, United States of America, ⁶Dana-Farber Cancer Institute and Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America

172

**Adjuvant chemotherapy vs. observation following radical cystectomy for pT3-4 and/or pN+ urothelial carcinoma of the bladder previously treated with neoadjuvant chemotherapy**

**By:** Seisen T.¹, Jamzadeh A.², Vetterlein M.², Von Landenberg N.², Gild P.², Menon M.², Rouprêt M.², Sun M.², Choueiri T.², Bellmunt J.², Trinh Q.-D.²

**Institutes:** Brigham and Women’s Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Health Science Program
Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder
By: Seisen T.1, Sonpavde G.2, Kachroo N.3, Lipsitz S.4, Leow J.1, Menon M.3, Gild P.1, Von Landenberg N.1, Rouprêt M.5, Kitel A.3, Sun M.1, Pal S.3, Bellmunt J.1, Choueiri T.3, Trinh Q-D.3
Institutes: Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, University of Alabama At Birmingham, Divison of Hematology-Oncology, Department of Medicine, Birmingham, United States of America, Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, Brigham and Women's Hospital, Harvard Medical School and Harvard T.H. Chan School of Public Health, Center for Surgery and Public Health, Boston, United States of America, Pitié-Salpêtrière, APHP, University Paris VI, Dept. of Urology, Paris, France, City of Hope Comprehensive Cancer Center, Dept. of Medical Oncology & Experimental Therapeutics, Duarte, United States of America, Dana Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America

Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase 2 study
By: Necchi A.1, Lo Vullo S.2, Raggi D.1, Giannatempo P.1, Nicolai N.2, Piva L.3, Biasoni D.3, Catanzaro M.3, Torelli T.3, Stagni S.3, Calareso G.3, Togliardi E.3, Colecchia M.3, Busico A.3, Perrone F.3, Pennati M.1, Zaffaroni N.1, Mariani L.3, Salvioni R.3
Institutes: Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Experimental Oncology and Molecular Medicine, Milan, Italy

Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial
By: Hanna N.1, Trinh Q.-D.1, Sammon J.2, Seisen T.1, Vetterlein M.1, Moreira R.3, Preston M.1, Lipsitz S.1, Bellmunt J.3, Menon M.2, Choueiri T.3, Abdollah F.2
Institutes: Brigham and Women's Hospital, Harvard Medical School, Dept. of Urology, Boston, United States of America, Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America

An inconvenient truth: Difference between patient-reported and doctor-reported outcomes in advanced urothelial carcinoma
By: Hamano I.1, Hatakeyama S.1, Narita T.1, Fukushima K.1, Yamamoto H.1, Soma O.1, Matsumoto T.1, Tobisawa Y.1, Yoneyama T.2, Imai A.1, Yoneyama T.1, Hashimoto Y.2, Koie T.1, Ohyama C.1
Institutes: Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan, Hirosaki University School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan

Survival benefit of neoadjuvant chemotherapy for muscle invasive bladder cancer in elderly patients
By: Hamano I.1, Hatakeyama S.1, Oikawa M.1, Narita T.1, Hagiwara K.1, Tanaka T.1, Noro D.1, Yuki T.1, Yamamoto H.1, Yoneyama T.2, Imai A.1, Yoneyama T.1, Hashimoto Y.2, Koie T.1, Ohyama C.1
Institutes: Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan, Hirosaki University School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan
The pathological and clinical response of the luminal and basal subtypes of muscle-invasive bladder cancer to neoadjuvant cisplatin-based chemotherapy and radical cystectomy depend on the immunohistochemical classification system

By: Zhang R.¹, Chen H.¹, Xia J.², Shi O.³, Cao M.¹, Jin D.¹, Li C.⁴, Zhuang G.⁵, Liu Q.², Xue W.¹, Radvanyi F.⁶, Allory Y.⁷, Huang Y.¹

Institutes: ¹Shanghai Renji Hospital, Dept. of Urology, Shanghai, China, ²Shanghai Renji Hospital, Dept. of Pathology, Shanghai, China, ³Shanghai Jiao Tong University School of Medicine, Dept. of Epidemiology and Statistics, Shanghai, China, ⁴Chinese Academy of Sciences, Chinese Academy of Sciences Protein Science Core Facility Center, Institute of Biophysics, Beijing, China, ⁵Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, State Key Laboratory of Oncogenes and Related Genes, Shanghai, China, ⁶Institut Curie, CNRS, UMR 144, Paris, France, ⁷AP-HP, Hôpitaux Universitaires Henri-Mondor, Dept. of Pathology, Créteil, France

Impact of adjuvant chemotherapy in patients with pT3NanyM0 upper tract urothelial cancer following radical nephroureterectomy

By: Song W.¹, Choi Y.H.¹, Chung H.W.¹, Lee C.U.¹, Na J.P.¹, Choi S.M.², Sung H.H.¹, Jeon H.G.¹, Jeong B.C.¹, Seo S.I.¹, Jeon S.S.¹, Choi H.Y.¹, Lee H.M.¹

Institutes: ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea, ²Gyeongsang National University Hospital, Dept. of Urology, Jinju, South Korea

Multimodal bladder preservation technique for muscle invasive bladder cancer: Results from a prospective trial

By: Inamoto T.¹, Takahara K.², Ibuki N.², Takai T.², Uchimoto T.³, Saito K.², Tanda N.², Yoshikawa Y.², Minami K.², Hirano H.², Nomiy H.², Azuma H.², Yamamoto K.⁴, Shinbo T.⁴, Yamamoto K.⁴, Narumi Y.⁴

Institutes: ¹Osaka Medical College, Osaka, Japan, ²Osaka Medical College, Dept. of Urology, Osaka, Japan, ³Osaka Medical College Mishima-Minami Hospital, Dept. of Urology, Osaka, Japan, ⁴Osaka Medical College, Dept. of Radiology, Osaka, Japan

Aspects on perioperative chemotherapy

C.N. Sternberg, Rome (IT)